Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T George

Showing results (711-720 of 771) with videos related to

Pageof 78
Sort By:
The AAPS Journal|October 27, 2023
A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics ApplicationsShiny Amala Priya Rajan, Jason Sherfey, Shivam Ohri, et al.
The Lancet. Diabetes & Endocrinology|November 20, 2020
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trialDarren K McGuire, Bernard Zinman, Silvio E Inzucchi, et al.
Atherosclerosis|January 8, 2026
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemiaRobert S Rosenson, Eliot A Brinton, Daniel Gaudet, et al.
Scientific Reports|October 25, 2017
An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodiesFrancis B Ntumngia, Camilla V Pires, Samantha J Barnes, et al.
Radiology|September 29, 2017
Coronary Artery Disease: Analysis of Diagnostic Performance of CT Perfusion and MR Perfusion Imaging in Comparison with Quantitative Coronary Angiography and SPECT-Multicenter Prospective TrialMatthias Rief, Marcus Y Chen, Andrea L Vavere, et al.
ESC Heart Failure|May 7, 2021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failureMoritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, et al.
Clinical Kidney Journal|September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Circulation|January 25, 2006
Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scarAlbert C Lardo, Marco A S Cordeiro, Caterina Silva, et al.
Molecular Therapy. Advances|May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humansErik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
Lab on a Chip|April 28, 2026
Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systemsJason Sherfey, Shiny Amala Priya Rajan, Lauren M Nichols, et al.
Pageof 78

Showing results (711-720 of 771) with videos related to

Sort By:
Pageof 78
The AAPS Journal|October 27, 2023
A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics ApplicationsShiny Amala Priya Rajan, Jason Sherfey, Shivam Ohri, et al.
The Lancet. Diabetes & Endocrinology|November 20, 2020
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trialDarren K McGuire, Bernard Zinman, Silvio E Inzucchi, et al.
Atherosclerosis|January 8, 2026
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemiaRobert S Rosenson, Eliot A Brinton, Daniel Gaudet, et al.
Scientific Reports|October 25, 2017
An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodiesFrancis B Ntumngia, Camilla V Pires, Samantha J Barnes, et al.
Radiology|September 29, 2017
Coronary Artery Disease: Analysis of Diagnostic Performance of CT Perfusion and MR Perfusion Imaging in Comparison with Quantitative Coronary Angiography and SPECT-Multicenter Prospective TrialMatthias Rief, Marcus Y Chen, Andrea L Vavere, et al.
ESC Heart Failure|May 7, 2021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failureMoritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, et al.
Clinical Kidney Journal|September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Circulation|January 25, 2006
Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scarAlbert C Lardo, Marco A S Cordeiro, Caterina Silva, et al.
Molecular Therapy. Advances|May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humansErik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
Lab on a Chip|April 28, 2026
Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systemsJason Sherfey, Shiny Amala Priya Rajan, Lauren M Nichols, et al.
Pageof 78